The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'December, 2017'. If you still can't find what you are looking for, try using the search box.
The Enterprise Europe Network (EEN), in partnership with Innovate UK is organising a funded Accelerator Programme visit to Japan for innovative UK companies operating in the Cell and Gene Therapy sector.
Read the rest of entry »
Oxford, UK: Immunocore Limited, the world’s leading TCR company focused on delivering first-in-class biological therapies that transform lives, has taken laboratory and office space at The Oxford Science Park. In its new premises on the Park, Immunocore will be focused on the development of immunotherapies for infectious diseases, complementing its cancer research at Milton Park in Oxford
Wessex Clinical Research Network (CRN) and Wessex Academic Health Science Network (AHSN) have teamed up to support commercial innovators gather crucial evidence on their products. Their new Technology Support Programme (TSP) will help companies to access the NHS’s research infrastructure to obtain high quality evidence on the economic and health gains their products can bring.
Arecor and its partner, non-profit company, Global Alliance for Livestock Veterinary Medicines (GALVmed), have successfully stabilised liquid formulations of vaccines to combat two major diseases of livestock across the developing world including Africa, Asia and the Middle East
In this work, the ArestatTM technology has been applied to enable a vaccine to be distributed pre-prepared in a liquid format without the requirement for in-field reconstitution from the freeze-dried powder form
ArestatTM technology has also been applied to reduce the cost of a batch of vaccine diluent by 96 per cent., thereby improving its distribution and uptake by farmers
Arecor’s formulation technology work has been supported by Innovate UK through UK aid of the UK government and the Bill & Melinda Gates Foundation
Cambridge, UK., 8th December 2017: Arecor Ltd (“the Company”), a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology ...
Oxford MESTar, in collaboration with the Cell and Gene Therapy Catapult and AK Biomedical, has won a grant from Innovate UK to support the development of a novel manufacturing system intended to dramatically reduce the cost of production of CAR-T therapies.
Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the third quarter and nine months ended 31 October 2017 on 6 December 2017.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Glyn Edwards / Richard Pye (UK office)
44 (0)1235 443 951
Activate Science, an annual event series organised by Thermo Fisher Scientific and attended by laboratory personnel across Europe, reached delegates at 28 customer sites in 2017.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.